• 고려인삼학회:학술대회논문집
• /
• 고려인삼학회 2002년도 학술대회지
• /
• pp.129-144
• /
• 2002

We investigated anti-hyperglycemic and anti-obese effects of Panax ginseng berry extract and its major constituent, ginsenoside Re, in obese diabetic C57BL/6J ob/ob mice and their lean littermates. Animals received daily intraperitoneal injections of Panax ginseng berry extract for 12 days. On Day 5, 150 mg/kg extract-treated ob/ob mice had significantly lower fasting blood glucose levels compared to vehicle-treated mice $(156{\pm}9.0\;mg/dl\;vs.\;243{\pm}15.8mg/dl,$ P<0.01). On Day 12, the extract-treated ob/ob mice became normoglycemic $(137{\pm}6.7\;mg/dl)$ and had significantly improved glucose tolerance. The overall glucose excursion during the two-hour intraperitoneal glucose tolerance test (IPGTT), calculated as area under the curve (AUC), decreased by $46\%$ (P<0.01) compared to vehicle-treated ob/ob mice. Glucose levels of lean mice were not significantly affected by the extract. The improvement in blood glucose levels in 150 mg/kg extracttreated ob/ob mice was associated with significant reduction in serum insulin levels of fed and fasting mice. Consistent with an improvement in insulin sensitivity, hyperinsulinemic euglycemic clamp study revealed a more than 2-fold increase in the rate of insulin-stimulated glucose disposal in treated ob/ob mice $(112{\pm}19.1\;vs.\;52{\pm}11.8{\mu}mol/kg/min$ for the vehicle group, P<0.01). In addition, 150 mg/kg extract-treated ob/ob mice, but not the lean mice, lost significant weight (from $51.7{\pm}1.9g\;on\;Day\;0\;to\;45.7{\pm}1.2$ on Day 12, P<0.01 compared to vehicle-treated ob/ob mice), associated with a significant reduction in food intake (P<0.05) and a very significant increase in energy expenditure (P<0.01) and body temperature (P<0.01). A 12-day treatment with 150 mg/kg Panax ginseng berry extract also significantly reduced plasma cholesterol levels in ob/ob mice. Additional studies demonstrated that ginsenoside Re, a major constituent of the ginseng berry, but not from the root, plays a significant role in anti-hyperglycemic action. This anti-diabetic effect of ginsenoside Re was not associated with body weight changes, suggesting that other constituents in the extract have distinct pharmacological mechanisms on energy metabolism. The identification of a significant anti-hyperglycemic activity in ginsenoside Re may provide an opportunity to develop a novel class of anti-diabetic agent.

• 생명과학회지
• /
• 제31권7호
• /
• pp.631-640
• /
• 2021

Houttuynia cordata Thunberg는 전통의학에서 다양한 약리학적 작용에 대해 연구되어 왔다. 본 연구에서, 거세 및 테스토스테론 프로피오네이트(TP) 주입에 의해 유도된 양성 전립선 비대증(BPH) 모델에 대한 Houttuynia cordata 에탄올 추출물(HCE)의 영향을 조사했다. 총 30마리의 쥐를 6개의 그룹으로 나누었다. 한 그룹은 정상 대조군으로 사용되었고 다른 그룹은 거세 후 14일 동안 복강내 TP를 주입하여 BPH를 유도하였다. 양성 대조군은 BPH 모델에 매일 피나스테라이드(5 mg/kg)를 투여했다. 피나스테라이드 대신 HCE (0.5, 1, 2mg/kg)를 투여한 군은 실험 군으로서 대조군과 비교하였다. 체중 100 g 기준으로 전립선 무게에 대한 통계적 유의성은 없었다. ELISA 검사로 5-α 환원효소 및 디하이드록시 테스토스테론(DHT) 농도를 측정하였으며, 모든 실험군에서 유의미한 감소가 있었다. 5-α 환원효소의 경우 HCE (0.5 mg/kg) 군이 가장 낮았고, DHT는 HCE (2 mg/kg) 군에서 가장 낮은 수치를 보였다. 전립선에 대한 조직병리학적 관찰에서 대조군과 HCE (2 mg/kg) 투여 군은 정상 세포 형태를 보였고 세포팽창이 없었다. 그러나 음성 대조군과 HCE (1 mg/kg) 군에서는 세포가 부풀어 오르고 세포 사이의 간격이 좁아졌다. 특히 HCE (0.5 mg/kg) 군에서는 일부 세포가 터지는 현상이 나타났다. 따라서 2 mg/kg 이상의 HCE를 투여하는 것이 BPH의 보호 효과에 적합할 것이다.

• 대한시과학회지
• /
• 제20권4호
• /
• pp.589-596
• /
• 2018

목적 : 우리는 두 종류의 안압계로 정상 범위 안압과 녹내장 쥐 모델의 안압을 측정하여 안압값을 비교하였다. 두 안압계 중 어느 것이 더 쉽고 정확하게 동물 모델의 안압을 측정할 수 있는지 알아보고자 하였다. 방법 : 녹내장 눈은 6주령 수컷 Sparque-Dawley (SD) 쥐의 오른쪽 눈 전방에 점탄물질 히알루론산을 주입하여 유도하였으며 정상 대조군으로는 동일 쥐의 좌안을 사용하였다. 안압은 오후 3시경 리바운드 압평안압계 (Tonolab)와 함입 안압계 ($Tonopen^{(R)}$ XL)로 측정하였다. 결과 : 대조군인 정상 안압 눈의 평균 안압은 토노펜으로 측정 시 $10.80{\pm}1.03mmHg$, 토노랩으로 측정 시 $15.10{\pm}0.73mmHg$으로 측정되었다. 이 수치들은 통계적으로 유의한 차이는 없었다 (p = .1). 실험군인 녹내장 눈의 평균 안압은 토노펜으로 측정 시 $30.20{\pm}2.67mmHg$, 토노랩으로 측정 시 $37.90{\pm}2.73mmHg$로 측정되었다. 이 수치들은 통계적으로 유의한 차이는 없었다 (p = .95). 고안압인 녹내장 눈을 두안압계로 잰 수치들은 강한 양의 상관관계를 지니고 있었다 (r = .904, p < .01). 결론 : 이 연구는 두 가지 유형의 안압계를 사용하여 정상 범위 안압과 전방에 점탄물질을 삽입하여 유도한 녹내장 모델의 안압값을 비교한 최초의 연구이다. 토노펜은 안압이 정상범위일 때는 주의해서 사용해야 하며, 토노펜과 토노랩은 안압이 높은 범위일 때는 두 안압계 모두 안정적으로 사용될 수 있다.

• Korean Journal of Ophthalmology
• /
• 제32권6호
• /
• pp.451-458
• /
• 2018

Purpose: To investigate the efficacy, safety, and anatomical outcomes associated with intravitreal anti-vascular endothelial growth factor (VEGF) treatment of retinopathy of prematurity (ROP). Methods: We performed a retrospective review of intravitreal anti-VEGF (bevacizumab or ranibizumab) treatment of 153 eyes (83 infants) diagnosed with ROP at two tertiary hospitals from June 2011 to January 2017. The primary outcome was the rate of recurrence requiring additional treatment; secondary outcomes included incidence of major complications and final refractive error. Results: A total of 101 eyes were treated with bevacizumab, and 52 with ranibizumab. The bevacizumab and ranibizumab groups were characterized by mean birthweights of $941.8{\pm}296.1$ and $1,257.7{\pm}514.5g$, gestational ages at birth of $26.9{\pm}1.9$ and $28.1{\pm}3.2$ weeks, and postmenstrual ages at treatment of $40.4{\pm}2.4$ and $39.2{\pm}2.3$ weeks, respectively. The two groups differed significantly in birthweights and gestational ages at birth, but not in postmenstrual ages at treatment. The mean follow-up duration was $30.9{\pm}18.4$ months for the bevacizumab group, and $13.9{\pm}12.5$ months for ranibizumab. More cases were classified as zone 1 ROP in the ranibizumab group (44.2% vs. 11.9%, p < 0.001). Major surgical interventions included scleral encircling and vitrectomy (one and two eyes, respectively, both in the bevacizumab group). Retinal detachment was noted in one eye treated with bevacizumab. There was no significant difference in the most recent spherical equivalence for the two groups ($+0.10{\pm}3.66$ and $+0.22{\pm}3.00$ diopters for bevacizumab and ranibizumab, respectively). Univariable analysis revealed that only ROP stage influenced the occurrence of major complications (odds ratio, 9.046; p = 0.012). Conclusions: Intravitreal anti-VEGF treatment of ROP with both bevacizumab and ranibizumab achieved stable retinal vascularization with a low rate of complications and recurrence. Ranibizumab achieved similar anatomical outcomes as bevacizumab, without additional risk for major complications.

• 대한한의학회지
• /
• 제40권1호
• /
• pp.124-152
• /
• 2019

Objectives: This study aimed to ascertain what should be considered in the "Guideline for Clinical Trials with Herbal Medicinal Products for Colorectal Cancer" by analyzing the existing guidelines and clinical trials. Methods: The development committee searched guidelines for herbal medicinal products for colorectal cancer that have already been developed. Then, clinical trials for colorectal cancer using herbal medicine were searched. The searched trials were analyzed in terms of inclusion and exclusion of participants, intervention, comparator, outcomes and trial design. Then, we compared the results of our analysis with the regulations and guidelines of the Ministry of Food and Drug Safety in order to identify the issues we will have to consider when making the "Guideline for Clinical Trials with Herbal Medicinal Products for Colorectal Cancer". Several guidelines for anti-tumor agents and clinical trials with herbal medicinal products were searched on the national institution homepage. In addition, 12 articles were searched using a combination of the following search terms: 'colorectal neoplasms', 'herbal medicine', 'Medicine, Korean traditional', 'Medicine, Chinese Traditional', 'medicine, East Asian medicine', 'medicine, Kampo', etc. Results: The characteristics of participants were various, such as people with medical histories of surgeries or recurrent cancers or who complained of chemotherapy-induced side effects. The types of interventions were also various and included decoctions, powders, intravenous fluids, intraperitoneal injections and gargles. Comparators used included placebos and conventional treatments. The outcome measurements used in the studies were quality of life, symptom score, tumor response, and survival duration, etc. Safety was evaluated by recording adverse events. Conclusions: Findings were made by reviewing existing guidelines and comparing them with clinical trials for colorectal cancer and herbal medicinal products. These results will be utilized in the development of the "Guideline for Clinical Trials with Herbal Medicinal Products for Colorectal Cancer".

• 한방안이비인후피부과학회지
• /
• 제32권2호
• /
• pp.68-93
• /
• 2019

Objective : This study summarized the characteristics of clinical trials for atopic dermatitis medicines approved by the Ministry of Food and Drug Safety(MFDS). This study may be a reference for the design of clinical trials of atopic dermatitis herbal medicine treatment which may be carried out later. Method : The characteristics of the clinical trial were analyzed for clinical trials registered with ClinicalTrials.gov, CRIS, and the Korea Health Industry Development Institute among the clinical trial approval statuses posted on the website of the MFDS. Result : 1. Clinical trial drugs were developed in various formulations such as oral medicines, injections, dermatologic agents, and similar proportions. Relatively little clinical trials were found for herbal medicine. 2. In the control evaluation test, most of the treatments for the control group were performed with placebo using Vehicle. 3. In most clinical trials, one intervention group was in the form of a parallel assignment with only one treatment. 4. The age of the subjects was 11 out of 28 studies including minors, and clinical trials targeting minors were also found to be significant. 5. In the case of atopic dermatitis, the cases of subacute chronic or atopic dermatitis more than 6 months or more than 1 year were often used. 6. Most clinical trials were divided into mild to moderate atopic dermatitis or moderate to severe atopic dermatitis. The SCORAD index, EASI, IGA, BSA, and NRS were used as the evaluation criteria. 7. Regulations for the drugs used prior to the trial period for the treatment of atopic dermatitis vary somewhat from one clinical trial to another. 8. IGA was used most often as a primary efficacy tool, and SCORAD index, EASI, and NRS were also used.

• Asian-Australasian Journal of Animal Sciences
• /
• 제32권11호
• /
• pp.1673-1685
• /
• 2019

Objective: To evaluate the efficacy of treatments based on gonadotrophin-releasing hormone (GnRH), GnRH-prostaglandin $F2{\alpha}$ ($PGF2{\alpha}$), and/or intense exposure to novel rams to induce fertile estrus without the use of steroid hormones in seasonally anestrous Suffolk ewes. Methods: In the first experiment, ewes were treated with one injection of GnRH, two injections of GnRH administered 7 days apart, or a sequence of GnRH-$PGF2{\alpha}$-GnRH (GPG). In the second experiment anestrous ewes were exposed, for 36 days starting on the day of weaning, to groups of four rams of three different breeds that were alternated every day. Besides exposure to the male effect (ME), the ewes were injected with saline solution (ME group, n = 20), with GnRH (ME-GnRH group, n = 20) or with a sequence of GnRH-$PGF2{\alpha}$-GnRH (ME-GPG group, n = 20). The rams used for male-effect were fitted with aprons to prevent mating, and ewes detected in estrus were bred to selected fertile rams. Ovarian activity was monitored by progesterone determinations in both experiments. Results: In the first experiment sustained induction of ovarian activity was not achieved and no ewe was detected in estrus. In the second experiment induction of sustained ovarian activity was achieved in all groups. Most of the ewes were detected in estrus, 76.7% of the ewes were mated during a 36-d breeding period and 71.7% of all the ewes became pregnant during that period. No significant differences between groups were found for any of these variables. However, estrus detection efficiency was higher in the ME-GnRH group than in the ME group (p<0.05). Conclusion: An intense male-effect, that included the continuous presence and frequent alternation of several rams of different breeds, was sufficient to induce ovarian activity and fertile estrus in Suffolk ewes during the period of deep anestrus without the use of hormones, although addition of GnRH improved the efficiency of estrus detection.

• Journal of Astronomy and Space Sciences
• /
• 제38권1호
• /
• pp.31-38
• /
• 2021

In this paper, we present observations of the Space Radiation Detectors (SRDs) onboard the Next Generation Small Satellite-1 (NEXTSat-1) satellite. The SRDs, which are a part of the Instruments for the study of Stable/Storm-time Space (ISSS), consist of the Medium-Energy Particle Detector (MEPD) and the High-Energy Particle Detector (HEPD). The MEPD can detect electrons, ions, and neutrals with energies ranging from 20 to 400 keV, and the HEPD can detect electrons over an energy range from 0.35 to 2 MeV. In this paper, we report an event where particle flux enhancements due to substorm injections are clearly identified in the MEPD A observations at energies of tens of keV. Additionally, we report a specific example observation of the electron distributions over a wide energy range in which we identify electron spatial distributions with energies of tens to hundreds of keV from the MEPD and with energy ranging up to a few MeV from the HEPD in the slot region and outer radiation belts. In addition, for an ~1.5-year period, we confirm that the HEPD successfully observed the well-known outer radiation belt electron flux distributions and their variations in time and L shell in a way consistent with the geomagnetic disturbance levels. Last, we find that the inner edge of the outer radiation belt is mostly coincident with the plasmapause locations in L, somewhat more consistent at subrelativistic energies than at relativistic energies. Based on these example events, we conclude that the SRD observations are of reliable quality, so they are useful for understanding the dynamics of the inner magnetosphere, including substorms and radiation belt variations.

• 대한후두음성언어의학회지
• /
• 제32권3호
• /
• pp.135-141
• /
• 2021

Background and Objectives Vocal process granulomas (VPGs) are benign lesions of the larynx, typically contact granulomas (CG) and intubation granulomas (IG). The two diseases are known to have different clinical manifestations despite having the same pathological features. The purpose of this study was to analyze the treatment results for CG and IG and to obtain clinical information. Materials and Method We retrospectively reviewed the medical records of patients diagnosed with VPG between January 2015 and December 2018. The patient's age, sex, medical history, lesion size, lesion type, reflux finding score, response to treatment, duration of treatment, and follow-up period were compared. Results In total, 32 patients were included in the study, of which 18 were CG and 14 were IG. In the CG group, males were dominant (n=15, 83.3%), whereas in the IG group, females were dominant (n=11, 78.6%) (p=0.0009). The response to medical treatment using proton pump inhibitor and steroid inhaler was better in the IG group (11/14, 78.6%) than in the CG group (7/18, 38.9%) (p=0.036). Of the 14 patients who did not respond to medical treatment, 5 received botulium toxin injections, and all 5 had complete remission. The duration of medical treatment was significantly longer in the IG group (p=0.0029). Conclusion IG was more common in female, and CG was more dominant in male. IG had better response to medical treatment using proton pump inhibitor and steroid inhaler than CG.

• Journal of Dental Anesthesia and Pain Medicine
• /
• 제22권4호
• /
• pp.305-314
• /
• 2022

Introduction: This clinical trial aimed to evaluate the anesthetic effect of the addition of 2 mg (4 mg/ml) of dexamethasone to 2% lidocaine (plain or with 1:80,000 epinephrine). The solutions were injected for a primary inferior alveolar nerve block (IANB) to provide mandibular anesthesia for the endodontic treatment of mandibular molars with symptomatic irreversible pulpitis. Methods: In a double-blinded setup, 124 patients randomly received either of the following injections: 2% lidocaine with 1:80,000 epinephrine, 2% lidocaine with 1:80,000 epinephrine mixed with 2 mg dexamethasone, or plain 2% lidocaine mixed with 2 mg dexamethasone, which were injected as a primary IANB. Ten minutes after injection, patients with profound lip numbness underwent electric and thermal pulp sensibility tests. Patients who responded positively to the tests were categorized as "failed" anesthesia and received supplemental anesthesia. The remaining patients underwent endodontic treatment using a rubber dam. Anesthetic success was defined as "no pain or faint/weak/mild pain" during endodontic access preparation and instrumentation (HP visual analog scale score < 55 mm). The effect of the anesthetic solutions on the maximum change in heart rate was also evaluated. The Pearson chi-square test at 5% and 1% significance was used to analyze anesthetic success rates. Results: The 2% lidocaine with 1:80,000 epinephrine, 2% lidocaine with 1:80,000 epinephrine mixed with 2 mg dexamethasone, and plain 2% lidocaine mixed with 2 mg dexamethasone groups had anesthetic success rates of 34%, 59%, and 29%, respectively. The addition of dexamethasone resulted in significantly better results (P < 0.001, 𝛘² = 9.07, df = 2). Conclusions: The addition of dexamethasone to 2% lidocaine with epinephrine, administered as an IANB, can improve the anesthetic success rates during the endodontic management of symptomatic mandibular molars with irreversible pulpitis.